Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparison of the tolerability of ¹⁶¹ Tb- and ¹⁷⁷ Lu-labeled somatostatin analogues in the preclinical setting.

Autor: Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland., Mapanao AK; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland., Kegler K; AnaPath Services GmbH, Liestal, 4410, Switzerland., Bernhardt P; Department of Medical Radiation Sciences, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41345, Sweden.; Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, 41345, Sweden., Flühmann F; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland., Fricke J; Division of Nuclear Medicine, University Hospital Basel, Basel, 4031, Switzerland., Zeevaart JR; Radiochemistry, South African Nuclear Energy Corporation (Necsa), Brits, 0240, South Africa., Köster U; Institut Laue-Langevin, Grenoble, 38042, France., van der Meulen NP; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland.; Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland., Müller C; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland. cristina.mueller@psi.ch.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland. cristina.mueller@psi.ch.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Nov; Vol. 51 (13), pp. 4049-4061. Date of Electronic Publication: 2024 Jul 24.

Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours.

Autor: Gomes CV; Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012, Bern, Switzerland. carlos.gomesferreira@students.unibe.ch.; Post-graduation Program in Nuclear Sciences and Techniques, Department of Nuclear Engineering, Federal University of Minas Gerais, Belo Horizonte, Brazil. carlos.gomesferreira@students.unibe.ch., Mendes BM; Nuclear Technology Development Center - CDTN/CNEN, Belo Horizonte, Brazil., Paixão L; Department of Anatomy and Imaging, Federal University of Minas Gerais, Belo Horizonte, Brazil., Gnesin S; Institute of Radiation Physics, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland., Müller C; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland., van der Meulen NP; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland.; Laboratory of Radiochemistry, Paul Scherrer Institute (PSI), Villigen, Switzerland., Strobel K; Institute of Radiology and Nuclear Medicine, Luzerner Kantonsspital - LUKS, Lucerne, Switzerland., Fonseca TCF; Post-graduation Program in Nuclear Sciences and Techniques, Department of Nuclear Engineering, Federal University of Minas Gerais, Belo Horizonte, Brazil.; Nuclear Technology Development Center - CDTN/CNEN, Belo Horizonte, Brazil., Lima TVM; Institute of Radiology and Nuclear Medicine, Luzerner Kantonsspital - LUKS, Lucerne, Switzerland.; Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.

Publikováno v: EJNMMI physics [EJNMMI Phys] 2024 Jul 15; Vol. 11 (1), pp. 61. Date of Electronic Publication: 2024 Jul 15.

Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with ¹⁶¹ Tb and ¹⁷⁷ Lu: A Comparative Study.

Autor: Holzleitner N; Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany., Cwojdzinski T; Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany., Beck R; Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany., Urtz-Urban N; Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany., Hillhouse CC; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen, Switzerland; and., Grundler PV; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen, Switzerland; and., van der Meulen NP; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen, Switzerland; and., Talip Z; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen, Switzerland; and., Ramaekers S; Nuclear Medical Applications, Belgian Nuclear Research Centre, Mol, Belgium., Van de Voorde M; Nuclear Medical Applications, Belgian Nuclear Research Centre, Mol, Belgium., Ponsard B; Nuclear Medical Applications, Belgian Nuclear Research Centre, Mol, Belgium., Casini A; Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany; thomas.guenther@tum.de angela.casini@tum.de., Günther T; Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany; thomas.guenther@tum.de angela.casini@tum.de.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Mar 01; Vol. 65 (3), pp. 481-484. Date of Electronic Publication: 2024 Mar 01.

Synthesis and Preclinical Evaluation of Radiolabeled [ ¹⁰³ Ru]BOLD-100.

Autor: Happl B; Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria., Brandt M; Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Joint Applied Medicinal Radiochemistry Facility, University of Vienna, Medical University of Vienna, 1090 Vienna, Austria., Balber T; Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Joint Applied Medicinal Radiochemistry Facility, University of Vienna, Medical University of Vienna, 1090 Vienna, Austria., Benčurová K; Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria., Talip Z; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland., Voegele A; Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland., Heffeter P; Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8A, 1090 Vienna, Austria.; Research Cluster 'Translational Cancer Therapy Research', Waehringer Strasse 42, 1090 Vienna, Austria., Kandioller W; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria.; Research Cluster 'Translational Cancer Therapy Research', Waehringer Strasse 42, 1090 Vienna, Austria., Van der Meulen NP; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland.; Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland., Mitterhauser M; Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria.; Joint Applied Medicinal Radiochemistry Facility, University of Vienna, Medical University of Vienna, 1090 Vienna, Austria., Hacker M; Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria., Keppler BK; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria.; Research Cluster 'Translational Cancer Therapy Research', Waehringer Strasse 42, 1090 Vienna, Austria., Mindt TL; Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria.; Joint Applied Medicinal Radiochemistry Facility, University of Vienna, Medical University of Vienna, 1090 Vienna, Austria.

Publikováno v: Pharmaceutics [Pharmaceutics] 2023 Nov 15; Vol. 15 (11). Date of Electronic Publication: 2023 Nov 15.